TSXV · MPH.V
Medicure Inc.
CA$4.40+CA$0.10 (+2.33%)
Medicure Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.11% below the high.
Loading market information…
OTC · EGRX · USD
Stock price, earnings
Quote as of Oct 26, 2026, 07:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eagle Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Eagle Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of $0.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eagle Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Aug 9, 2022 | $1.56-50.16% vs estimate | $74.14M-36.61% vs estimate |
|---|
| Q1 2022 | May 9, 2022 | $4.04+4.12% vs estimate | $115.87M-6.04% vs estimate |
|---|
| Q4 2021 | Mar 7, 2022 | $0.85-2.3% vs estimate | $42.32M-17.15% vs estimate |
|---|
KEEP COMPARING
CA$4.40+CA$0.10 (+2.33%)
Medicure Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.11% below the high.
$0.02-$0.00 (-5.56%)
Rhelion Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.47% below the high.
$0.00+$0.00 (+5.56%)
Univec, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.22% below the high.
CA$0.03CA$0.00 (0.0%)
Christina Lake Cannabis Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
£0.00+£0.00 (+9.0%)
Oxford BioDynamics Plc’s quoted price sits in the lower half of its reported 52-week range, 66.18% below the high.
$0.05-$0.01 (-14.55%)
Eco-Growth Strategies Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.09% below the high.
CA$0.02CA$0.00 (0.0%)
Nextleaf Solutions Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
$0.15$0.00 (0.0%)
Blum Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
